T2 Biosystems, Inc. is a medical diagnostics company specializing in direct-from-blood assays for infectious diseases and sepsis management. Its platform centers on the T2Dx instrument and proprietary T2MR technology, enabling rapid detection of pathogens without the need for time-consuming blood cultures. The portfolio includes panels for bacteria and Candida species, as well as a SARS‑CoV‑2 assay, with a pipeline targeting antibiotic resistance genes, Lyme disease, Candida auris, and biothreat organisms. By delivering faster, clinically actionable results, T2 Biosystems supports antimicrobial stewardship, early sepsis intervention, and hospital infection control workflows across acute care settings and reference labs. The company’s focus positions it within advanced in vitro diagnostics, addressing critical care, microbiology, and public health needs where hours can influence outcomes. Its agreements with healthcare distributors and efforts to expand pathogen coverage underscore a strategy to broaden adoption in U.S. and international markets. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems contributes to the shift toward rapid, molecular diagnostics that aim to reduce mortality, length of stay, and costs associated with bloodstream infections and emerging resistant organisms.